Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata.

Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US Food and Drug Administration–approved treatments for severe AA are the Janus kinase inhibitors (JAKis) baricitinib, ritlecitinib, and deuruxolitinib. Herein, we discuss the efficacy, safety, and real-world aspects of JAKi treatment for patients with AA for an advanced practice provider audience. We review the clinical characteristics and diagnosis of AA and discuss treatment expectations for patients using JAKis. &nbsp.